Publications by authors named "Jane Akodu"
Article Synopsis
- Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved in November 2021 for use in virally suppressed adults in England and Wales, and the evaluation of its delivery processes took place across 12 clinics.* -
- A total of 518 adults were approved for CAB + RPV LAI from February 2022 to December 2023, with 423 receiving at least one injection; the treatment had a median duration of 7.5 months and a high adherence rate of 97% for timely injections.* -
- Results indicated only 0.7% experienced virological failure and 6% discontinued treatment, showcasing that effective clinic protocols and
Receipt of nebulised pentamidine in people with HIV was audited to identify if individuals were appropriately receiving nebulised pentamidine, and whether national guidelines were being followed when prophylaxis was commenced and discontinued. Of 76 people with who received nebulised pentamidine, the main indication for starting nebulised pentamidine was a co-trimoxazole adverse drug reaction. Co-trimoxazole desensitization was not attempted before starting nebulised pentamidine.
View Article and Find Full Text PDFBackground: Since 2015, we prescribed dolutegravir (DTG)-based two drug regimens (DTG-2DR) for 620 people [total cohort 3133 (19.8%)].
Method: Clinic database search 1 January 15 to 31 October 21.